Oscity BioSciences

10/23/2026

Our CEO, Christopher St. Pierre, recently joined Tim Scott on The Hatch Fairhope Podcast to discuss Oscity BioSciences' patented co-crystal technology and the future of cannabinoid-based medicine.

Thirteen minutes on the science, the challenges, the opportunities, and building biotech on Alabama's Gulf Coast.
• How Oscity Biosciences got started
• Why are many paying more attention to cannabinoids
• What are cocrystals and the benefits of patented technology
• Why build right here in Foley, Alabama
• What it takes to move new therapeutics to market

The episode is part of Hatch's Powered by Bessel.co Cohort 3 Biotech Accelerator series. Listen here:

https://hatchfairhope.com/podcast/rethinking-cannabinoid-based-medicine-chris-st-pierre-on-oscity-biosciences

"God made the plant." It's a simple observation that opens the door to a much bigger conversation about the evolution of cannabinoids, science, and the future o

10/16/2026

Oscity BioSciences is honored to announce that CEO Christopher St. Pierre will serve as a panelist on the Science Meets Strategy session at the BIO Alabama 2026 Annual Conference.

The panel brings together leaders from research institutions, investment, entrepreneurship, and industry to examine how scientific advances are translated into commercial and clinical impact. For Alabama’s growing bioscience community, these discussions help strengthen the connections between discovery, strategy, and the partnerships needed to move promising technologies forward.

As an Alabama-based company focused on high-purity cannabinoid technologies for growing therapeutic applications, Oscity BioSciences is pleased to contribute a private-sector perspective on bridging science with practical commercialization pathways.

The conference offers a valuable opportunity for collaboration across the state’s ecosystem, and Oscity looks forward to the exchange.

Event Details
Science Meets Strategy
Thursday, October 22, 2026 | 3:00 p.m.
Renaissance Birmingham Ross Bridge Golf Resort & Spa
Birmingham, Alabama

Learn more about the BIO Alabama 2026 Annual Conference: https://bioalabamaevents.vfa (https://lnkd.in/eUXuSSgV)

10/07/2026

Medicines can fail quietly when the dose is unpredictable.

Here is what the integration of Enantia’s cannabinoid co-crystal technology patents into Oscity BioSciences’ established foundation unlocks:

For patients – A defined solid form is one of the unglamorous requirements of a product that can work consistently day after day. If cannabinoids are to deliver therapeutic value, consistency is not a luxury. It is the therapy.

For providers and developers – Co-formers such as L-proline are already familiar in food and pharma. We are not inventing a new chemical entity. We are putting a known active into a known class of solid form. That keeps the regulatory conversation on quality and performance, not on “what did you turn this molecule into.”

For manufacturing – Purification without chromatography, at commercial scale, is reality. Our process takes input material to a high-purity solid at ordinary temperature and pressure.

For partners – Issued U.S. patents 11,168,047 and 11,993,563 cover characterized co-crystal forms across the cannabinoid landscape: C*D, CBG, CBN, C*DV, and related structures. That is a platform, not just a single novelty compound. Licensees and development partners can build products on protected ground.

At Oscity BioSciences, we are on a journey to develop medicines the way other serious drugs are developed: as defined solids, with a fingerprint, a process, and a path.

If you are working in formulation, CMC, or cannabinoid and want the technical briefing behind our announcement, our team is available.

*DCocrystal *d

10/06/2026

Why does a crystal structure matter if the active molecule is the same?

Cannabinoids are oily, light-sensitive, and poorly soluble in water. That is why oral products are inconsistent. Same milligram on the label. Different amount that actually reaches the patient. Different shelf life. Different batch.

A does not change the pharmacology of the . It changes the conditions under which that pharmacology can be trusted.

In practical terms, the right cocrystal can help with four things that determine whether a therapy is usable:
1. Purity — the crystal can pull the target cannabinoid out of a complex extract in one step, often from crude material to pharmaceutical-range purity, without relying on heavy chromatography.
2. Stability — the ordered solid is less of a moving target than an oil. That matters for shelf life, heat, and manufacturing.
3. Consistency — one defined crystal fingerprint means the same solid form, batch after batch. Formulation teams can design around a known solid, not a variable resin.
4. Delivery potential — a more controlled solid is easier to build into tablets, capsules, and other pharmaceutical dosage forms. That is how we move from an extract to a product a provider can prescribe with confidence.

Enhanced therapeutic value, in this context, does not mean a magic new effect. It means the same active ingredient, in a form that can be purified, stored, dosed, and developed like a medicine.

That is the difference between a ingredient and a candidate.

*dcocrystals *d

10/06/2026

Last week we announced the acquisition of Enantia’s cannabinoid cocrystal patents. So what actually is a cocrystal?

A cocrystal is not a new drug. It is not a blend. It is not a chemical rewrite of C*D, CBG, or any other cannabinoid. It is two known molecules that lock together in a precise crystal...the cannabinoid and a familiar, food-grade partner such as L-proline.

Raw cannabinoid oil is hard to purify, hard to dose the same way twice, and hard to keep stable. A cocrystal provides an ordered and consistent molecular structure. That ordered form is why companies have used cocrystals for years in other drug classes. The FDA has already approved multiple cocrystal medicines. The science is not experimental. We are now applying it across the cannabinoid spectrum, with issued U.S. patents, and building upon that platform.

More to come on why that innovative form changes what a therapy can actually do to help many.

*dcocrystals *d

09/30/2026

Oscity BioSciences today announced the acquisition of Enantia’s foundational U.S. cannabinoid cocrystal patents—Nos. 11,168,047 and 11,993,563—and the opening of a path for continued scientific cooperation.

Enantia originated the co-crystal science behind U.S. Patents 11,168,047 and 11,993,563. These issued claims cover defined cannabinoid cocrystals, including C*D, CBG, CBN, C*DV, and related molecules with selected co-formers, with processes for their preparation and purification. The technology enables chromatography-free purification and solid forms with the stability, consistency, and developability required for pharmaceutical-grade APIs, and is now being advanced at our cGMP facility in Foley, Alabama.

This relationship connects two decades of Barcelona solid-state expertise with a U.S. manufacturing and licensing platform built for pharmaceutical-grade cannabinoid APIs. One defined polymorph. No chromatography. GRAS co-formers. A clearer path from extract to consistent, developable solid form. Together we intend to advance research, scale production, and explore pharmaceutical applications of these solid forms.

We are grateful to Enantia team for the science that made this possible. We look forward to the work ahead and the responsible development of these assets.

Read the full announcement:
https://www.einpresswire.com/article/945213630/oscity-biosciences-acquires-enantia-s-cannabinoid-cocrystal-technology-patents-to-expand-production-capabilities

*D

Oscity and Enantia opens door to future scientific cooperation around Cannabinoid Cocrystal research, development, and potential pharmaceutical applications.

08/29/2026

Oscity BioSciences’ Role — Proprietary, Patented Cannabinoid Solutions

Understanding the endocannabinoid system is only the beginning. The real opportunity lies in developing cannabinoid-based products that can work with it more effectively and deliver meaningful therapeutic value.

Oscity BioSciences is focused on exactly that. We are advancing proprietary, patented technologies centered on cannabinoid cocrystals, including our L-proline covered by U.S. patents 11,168,047 and 11,993,563. These innovations address key limitations of traditional forms: improved solid-state properties, enhanced purity pathways, greater stability, and the potential for better formulation and delivery characteristics needed for pharmaceutical and advanced therapeutic applications.

Our platform is designed to support the development of high-purity isolates and specialized formulas (including those aimed at inflammatory, , and related conditions) that can more reliably engage the body’s own endocannabinoid system. In our cGMP-certified facility, we are building toward scalable manufacturing and rigorous regulatory pathways so that these proprietary compounds can move from science into real-world therapeutic value.

The is fundamental. BioSciences is committed to developing the next generation of tools that work with it.
www.oscity.com

*D *Dcocrystals

Oscity Biosciences — patented co-crystal cannabinoid technology, pharmaceutical-grade API wholesale, and exclusive licensing from Foley, Alabama.

08/28/2026

Our team is excited to be part of Baldwin County's growing BioTech Ecosystem on the Gulf Coast, and we greatly appreciate the support from and engagement with Hatch Fairhope and Baldwin Alliance. Thank you for the visit this week.

08/28/2026

Why the Endocannabinoid System Matters?
The human endocannabinoid system (ECS) is often called one of the most important regulatory networks in the body, yet it remains under-recognized.

Its importance lies in its reach and its role as a bridge between body and mind. CB1 and CB2 receptors are distributed so widely that the influences nearly every major physiological process. When the system functions optimally, it supports resilience. When it is out of balance, research associates that imbalance with chronic pain, inflammatory conditions, neurodegenerative processes, mood disorders, sleep, and metabolic issues.

Because the ECS is so central to maintaining health, therapies that can gently and selectively support or modulate it hold significant therapeutic potential. Not all cannabinoid approaches are equal, however. Stability, purity, bioavailability, and how the compound interacts with the receptors matter greatly. Areas that Oscity BioSciences platform can address.

Scientific advancement in this space requires more than simply extracting plant compounds. It requires dedicated pharmaceutical-grade innovation that focuses on.
www.Oscity.com

*d

08/26/2026

What Does the Endocannabinoid System Do?
The human Endocannabinoid System (ECS) doesn’t just exist, it actively works every day to keep your body in balance (homeostasis).

When something disrupts equilibrium — stress, injury, inflammation, or environmental changes — the body produces endocannabinoids on demand.

These molecules bind to CB1 and CB2 receptors and help modulate:
• Mood and stress response
• Pain sensation
• Appetite and metabolism
• Immune function and inflammation
• Sleep, memory, and neurological signaling
• Reproductive and gastrointestinal processes

Because endocannabinoids are made only when needed and then rapidly broken down, the system is highly precise and self-regulating. Dysregulation of the has been linked to a wide range of conditions, which is why it has become a major focus of therapeutic research and product development.

This is the biological foundation that makes thoughtfully designed cannabinoid compounds so promising. BioSciences is building on that science with proprietary approaches and patented products designed to engage the ECS more effectively.
www.Oscity.com

*d *dcocrystals